#USA #Somerville #Tessera Therapeutics #Gene Writing #Joseph Romanelli

Tessera Therapeutics Welcomes New Leadership

Tessera Therapeutics, a forward-thinking biotechnology firm known for its innovative Gene Writing™ approach to genetic medicine, has announced the appointment of Joseph Romanelli as its new President and Chief Executive Officer. This strategic move marks a significant leadership transition for the company, as Romanelli takes over from Michael Severino, who has been at the helm since June 2022.

Romanelli steps into his new role as Tessera embarks on the next phase of its journey, particularly focusing on advancing its Gene Writing technologies into practical medical applications. The firm has successfully initiated clinical trials with its first gene editing program known as TSRA-196, which aims to treat alpha-1 antitrypsin deficiency (AATD). This program is being developed in partnership with Regeneron Pharmaceuticals, emphasizing the collaborative spirit in the biotechnology space.

In addition to TSRA-196, Tessera is making strides in developing treatment options for sickle cell disease and exploring in vivo chimeric antigen receptor (CAR)-T therapies for oncology and autoimmune disorders. Notably, the Gates Foundation has invested up to $50 million to support the creation of an accessible gene editing therapy for sickle cell disease, which underlines the importance of Tessera's mission in addressing serious health challenges globally.

Geoff von Maltzahn, co-founder and former CEO of Tessera, expressed confidence in Romanelli’s capabilities. He stated, “Joe has an impressive track record spanning over three decades, focused on building teams and bringing innovative therapies to markets across the globe. His experience is critical as Tessera transitions toward realizing the potential of Gene Writing technologies.” This leadership change signifies the company's ambition to expand its portfolio by developing a variety of genetic medicines.

Romanelli, who previously led Merck & Co., Inc.’s international human health operations, is expected to bring invaluable insights and operational expertise to Tessera. His experience at Merck included significant roles that enabled the company to flourish in rapidly growing markets like China, which became one of Merck's top markets during his tenure there.

Bringing a wealth of knowledge in drug commercialization and team leadership, Romanelli stated his enthusiasm for Tessera's promising technologies. He believes in the potential of Gene Writing to not only alleviate symptoms but directly address the genetic root causes of diseases. This aligns perfectly with Tessera's mission to revolutionize medicine through advanced genetic therapies.

Tessera Therapeutics is renowned for its clinical-stage biotechnology innovations, particularly its Gene Writing technology that aims to engineer genomic solutions for diseases. Their cutting-edge approach utilizes all-RNA constructs, aiming to modify the genome's sections efficiently. The company believes its methodologies could lead to breakthroughs not only in rare genetic disorders but also in prevalent diseases and cancer.

As Tessera embarks on this new chapter with Romanelli at the forefront, the biotechnology community is keenly watching how the company will adapt its innovations into scalable solutions. With aspirations to bring its distinctive genetic medicines to patients worldwide, the upcoming years may redefine how genetic diseases are treated. This pivotal leadership change symbolizes not just a new leader but a renewed aspiration to change lives through genetic medicine.

For more information about Tessera Therapeutics and its ongoing projects, please visit tesseratherapeutics.com.